This semiconductor testing provider saw a notable insider sale amid a year of pronounced share price gains and declining ...
Moderna (NasdaqGS:MRNA) plans to present Phase 1/2 data for its mRNA-4359 cancer antigen therapy combined with pembrolizumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results